142 related articles for article (PubMed ID: 26866004)
21. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
Kaminski H; Jarque M; Halfon M; Taton B; Di Ascia L; Pfirmann P; Visentin J; Garrigue I; Déchanet-Merville J; Moreau JF; Crespo E; Montero N; Melilli E; Meneghini M; Pascual M; Couzi L; Manuel O; Bestard O; Merville P
J Infect Dis; 2019 Jul; 220(5):761-771. PubMed ID: 31157865
[TBL] [Abstract][Full Text] [Related]
22. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
Jewani PK; Pouch SM; Kissling KT
Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
[TBL] [Abstract][Full Text] [Related]
23. Is combined pretransplantation seropositivity of kidney transplant recipients for cytomegalovirus antigens (pp150 and pp28) a predictor for protection against infection?
Essa S; Pacsa A; Said T; Nampoory MR; Raghupathy R; Johny KV; Al-Nakib W; Al-Mosawy M
Med Princ Pract; 2008; 17(1):66-70. PubMed ID: 18059104
[TBL] [Abstract][Full Text] [Related]
24. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
Luan FL
Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
[TBL] [Abstract][Full Text] [Related]
25. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
[TBL] [Abstract][Full Text] [Related]
26. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand.
Chiasakul T; Townamchai N; Jutivorakool K; Chancharoenthana W; Thongprayoon C; Watanatorn S; Avihingsanon Y; Praditpornsilpa K; Srisawat N
Transplant Proc; 2015 Oct; 47(8):2460-4. PubMed ID: 26518951
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?
Wong G; Chakera A; Chapman JR; Chadban SC; Pilmore H; Craig JC; Lim WH
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27860123
[TBL] [Abstract][Full Text] [Related]
29. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
[TBL] [Abstract][Full Text] [Related]
30. Cytomegalovirus infection in renal transplant recipients: one center's experience.
Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
[TBL] [Abstract][Full Text] [Related]
31. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
32. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
[TBL] [Abstract][Full Text] [Related]
33. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D deficiency is associated with increased risk of bacterial infections after kidney transplantation.
Park YJ; Kim SU; Lee KH; Lee JH; Kwon E; Jung HY; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Kim CD
Korean J Intern Med; 2017 May; 32(3):505-513. PubMed ID: 27017390
[TBL] [Abstract][Full Text] [Related]
35. Late cytomegalovirus (CMV) infections after kidney transplantation under the preemptive strategy: Risk factors and clinical aspects.
Ono G; Medina Pestana JO; Aranha Camargo LF
Transpl Infect Dis; 2019 Apr; 21(2):e13035. PubMed ID: 30548901
[TBL] [Abstract][Full Text] [Related]
36. Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes.
Jorgenson MR; Descourouez JL; Cardinale B; Lyu B; Astor BC; Garg N; Saddler CM; Smith JA; Mandelbrot DA
Transpl Infect Dis; 2019 Jun; 21(3):e13080. PubMed ID: 30891915
[TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
38. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus.
Mikulska M; Raiola AM; Bruzzi P; Varaldo R; Annunziata S; Lamparelli T; Frassoni F; Tedone E; Galano B; Bacigalupo A; Viscoli C
Biol Blood Marrow Transplant; 2012 Jan; 18(1):92-9. PubMed ID: 21689774
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus infection in the first year after pediatric kidney transplantation.
Tanné C; Roy P; Frobert É; Duncan A; Laurent A; Cochat P
Nephrol Ther; 2019 Mar; 15(1):44-50. PubMed ID: 29887270
[TBL] [Abstract][Full Text] [Related]
40. Control of cytomegalovirus disease in renal transplant patients treated with prednisone, azathioprine and cyclosporine using intensive monitoring and decreased immunosuppression.
Gómez E; de Oña M; Mélon S; Alvarez R; Laures A; Rodríguez M; Pobes A; Alvarez-Grande J
Nephron; 1999; 82(3):238-45. PubMed ID: 10395996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
